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2214-0247/Copyright ª 2014, TaiwanAbstract Colorectal cancer is a common gastrointestinal malignancy. Radiation combined
with chemotherapy (also known as concurrent chemoradiotherapy or CCRT) is often used prior
to surgery for treating severe cases of colorectal cancer. However, responses of individual tu-
mors to CCRT differ. Therefore, in light of the variability in radiation sensitivity among
different tumors, identifying the factors that can be applied to predict CCRT efficacy prior
to treatment will aid in making decisions regarding an appropriate treatment strategy. In
the present study, we used a gene chip to analyze the expression of candidate genes in the
tumor cells of colorectal cancer patients prior to and after treatment with CCRT, in order to
identify molecular markers that can predict the efficacy of CCRT. First, we selected a total
of 15 CCRT candidate genes based on the results of previous studies, which used the microarray
method to select CCRT response-related genes that were also related to tumor malignancy. We
collected preoperative CCRT tumor tissues from 17 colorectal cancer patients for whom the
efficacy of CCRT had already been determined and used gene chips to analyze the expression
of CCRT-related genes in the tissues of these patients. We then compared the results for the
expression of CCRT-related genes with those for the clinical efficacy of CCRT. Of the 15 candi-
date genes, five genes (CK-20, ELAVL4, EV12B, TM4SF3, and ATPA2) were upregulated
in >29.4% and one gene (MET ) was downregulated in 23.5% of the total patients afterMedical Research, Fooyin University Hospital, Number 5, Jhongshan Road, Donggang Township,
Biomedical Sciences, National Sun Yat-Sen University, 70 Lienhai Road, Kaohsiung 804, Taiwan.
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164 H.-J. Wu et al.treatment with CCRT, indicating that these genes may be potential predictive markers for
CCRT efficacy.
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Colorectal cancer (CRC) is the third leading cause of
cancer-related deaths. Most cancer treatments are pri-
marily based on surgical resection, but surgery is not suit-
able for treating all types of cancers (for example, in cases
where the tumor has spread) due to some limitations. As
such, radiation therapy or chemotherapy is often used as an
adjuvant therapy. Effectiveness of radiotherapy treatment
is not limited by the lesion location. Preoperative radiation
therapy usually yields better results by shrinking the tumor,
thus increasing the chances of complete surgical resection
of the tumor. Therefore, a combination of comprehensive
surgery and radiotherapy can provide local control to
improve treatment efficacy.1e3 According to the 2010
United States National Comprehensive Cancer Network
Version 1 guidelines, radiation prior to surgery combined
with chemotherapy (CCRT) is the recommended treatment
option for locally advanced CRCs (T3e4 or N1e2). Studies
have reported that the role of chemical treatment drugs
(such as 5-fluorouracil) in preoperative CCRT for patients
with advanced or unresectable CRCs is to enhance the
effectiveness of radiation therapy in killing cancer cells. In
other words, radiation therapy provides the major thera-
peutic effects of CCRT, whereas chemotherapy supple-
ments those therapeutic effects.4e6
Clinically, approximately 30e40% of patients are unable to
obtain the benefit of a decreased tumor stage (downstaging)
after receiving CCRT. In patients for whom CCRT show poor
efficacy, preoperative CCRT is more harmful than helpful
because it not only delays the timing of tumor resection, but
also results in immunosuppression, causes patients to suffer
unnecessarily, and is a waste of medical resources. As such, if
we can predict the efficacy of CCRT, we can use medical
resources and treat the disease more effectively. Such pre-
dictive ability would thus not only reduce the chances of
recurrence, but also greatly enhance the likelihood of organ
retention, particularly the affected organs.
The reason for individual differences in sensitivity to
CCRT is that different tumors exhibit different expression
profiles of related genes. Because cellular responses rely,
in part, on changes in gene expression, the extent to
which the radiation-responsive genes are induced or
repressed influences how the cells deal with radiation
exposure, where individual variability in radiation sensi-
tivity is observed at the gene expression level.7e9
Therefore, in the present study, we sought to deter-
mine the molecular markers that can predict the
efficacy of CCRT, and then explored the impact of each
genetic marker using a chip platform that was established
by Wang et al.10 This platform possesses the various ad-
vantages of biochips, has a lower cost, and exhibitsbetter usability, higher reproducibility, and higher accu-
racy compared to traditional chips. Results obtained with
this technology are consistent with the real-time quan-
titative polymerase chain reaction test results. There-
fore, it is possible to predict the efficiency of clinical
treatment by establishing a chip system; these prediction
results may serve as important references and help clin-
ical doctors in treatment planning prior to initiation of
therapy.
Materials and methods
Collection of specimen
In our study, data were gathered for 17 patients for whom
the clinical efficacy of CCRT was already known, excluding
any tissue specimens from CRC patients who also had other
cancers at the same time. For each patient, a biopsy
sample of the tumor tissue was taken prior to and after
treatment with CCRT prior to surgery, and kept on ice or in
liquid nitrogen. All the patients received preoperative
radiotherapy (45e50 Gy), and all were also treated with
chemotherapy during the radiotherapy process. All the
patients then subsequently underwent surgery. Data on the
clinical characteristics of each patient, including patient
age, gender, tumor size, location, histological type, clinical
stage, metastasis situation, and other information, were
collected.
Selection of genes and oligonucleotide design
Fifteen candidate genes were selected based on the
microarray research of our previous studies and other
recent studies11,12 in which the microarray method was
used to compare the expressions of candidate genes in
radiosensitive and radiation-resistant cells, as well as to
determine which genes are related to tumor malignancy.
Using the Oligo Explorer software program (Gene Link, Inc.,
New York, NY, USA), we designed a detection chip to
identify the nucleic acid sequences of candidate genes
related to radiotherapy effects.
Preparation of gene chip
The synthetic oligonucleotides were dissolved at a con-
centration of 10 nM in double distilled water. We then used
BioDOT AD1500 (BioDot Inc., Irvine, CA, USA) to automati-
cally dot candidate genes, B-actin (positive control), and
dimethyl sulfoxide (blank) on nylon membrane in triplicate.
After quick drying and adhesive fixing, the prototype chip
was obtained.
Table 1 Clinicopathological features of 17 colorectal
cancer patients.
Characteristics Number of
cases (n Z 17)
%
Sex
Male 11 64
Female 6 36
Age (y)
<60 10 59
>60 7 41
Tumor size (cm)
>5 9 53
<5 8 47
Stage
I þ II 5 29
III þ IV 12 71
Vascular invasion
Negative 8 47
Positive 9 53
Perineural invasion
Negative 13 77
Positive 4 23
Liver metastasis
Yes 3 18
No 14 82
Table 2 Gene expression of 15 target genes using gene
chip in 17 colorectal cancer patients treated with CCRT.
Gene Downregulated cases
after CCRT (N Z 17)
Upregulated cases
after CCRT (N Z 17)
CK-20 9 (52.9) 0 (0)
ELAVL4 9 (52.9) 2 (11.7)
EV12B 9 (52.9) 2 (11.7)
TM4SF3 5 (29.4) 0 (0)
ATPA2 5 (29.4) 1 (5.8)
OLFM4 9 (52.9) 4 (23.5)
hTERT 7 (41.1) 4 (23.5)
CD55 4 (23.5) 4 (23.5)
S100B 3 (17.6) 0 (0)
KCTD2 3 (17.6) 1 (5.8)
CEA 2 (11.7) 2 (11.7)
KLK7 2 (11.7) 2 (11.7)
CK-19 1 (5.8) 2 (11.7)
MUC1 1 (5.8) 2 (11.7)
MET 0 (0) 4 (23.5)
Data are presented as n (%).
CCRT Z concurrent chemoradiotherapy.
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A GeneCling Enzymatic Gene Chip Detection Kit (CaryGene
Biotechnology Co., Ltd, Kaohsiung, Taiwan) was used for
carrying out the following steps. First, beads were added for
RNA extraction, and an RT buffer and an RT enzyme were
then added to synthesize cDNA. Biotin Mix Label was then
added to cDNA for the synthesis of biotin-labeled probes
(probe synthesis). Then the labeled cDNA was hybridized
with the prepared chip at 42C for 6e17 hours. A wash
buffer was then used to wash away the probes that were not
hybridized, followed by the addition of streptavidin-AP and
nitro blue tetrazolium (NBT)/5-bromo-4-chloro-3-indolyl-
phosphate (BCIP) mixture and incubation at 37C to conduct
a color reaction. After coloration the chips were completely
dried; the colorimetric values of the individual genes were
analyzed using software, and these values were then
translated so as to indicate the relative intensities of the
various gene expressions. If the gene presented a color
density of greater than two-fold compared to the positive
control (beta-actin), it was defined as positive. If the gene
expression was less than two-fold compared to the positive
control, it was classed as negative.
Results
Clinicopathological features of 17 CRC patients
Clinicopathological features of 17 CRC patients [11 men
(64%) and six women (36%)] were recorded. The average
age was 54.7 years (range: 30e72 years). Table 1 shows the
clinicopathological characteristics of these 17 patients, all
of whom met the stage IeIII CRC criteria of the Union for
International Cancer Control.
Expression of 15 candidate genes in CRC patients
after treatment with CCRT
We compared the variations of gene expressions in the tis-
sues of the 17 patients prior to and after treatment with
CCRT. If the expression of a candidate genewas positive prior
to treatment and became negative after treatment with
CCRT, we defined the gene as being downregulated after
treatment. By contrast, if the expression of a candidate gene
was negative prior to treatment and became positive after
treatment with CCRT, we defined the gene as being upre-
gulated after treatment. Of the 15 candidate genes, CK-20,
ELAVL4, EV12B, TM4SF3, and ATPA2 genes were differen-
tially downregulated in, respectively, 52.9%, 52.9%, 52.9%,
29.4%, and 29.4% of the total patients after treatment with
CCRT. One gene, MET, was upregulated in 23.5% of the total
patients after treatment with CCRT (Table 2). Although
OLFM4 and hTER genes showed a higher proportion in
downregulated cases after treatment with CCRT, they did
not show differential proportion in upregulated cases.
Discussion
Preoperative radiotherapy has widely been used to improve
local control of disease and survival of patients followingtreatment of rectal cancer. There is great variability,
however, in the CCRT responses of different individuals due
to the lack of knowledge of how radiation-responsive genes
are induced or repressed and how cells deal with radiation
exposure.9 Therefore, we developed markers for predicting
the effectiveness of CCRT in CRC patients.
In the present study, we demonstrated the over-
expression patterns in CRC patients prior to and after
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genes (CK-20, ELAVL4, EV12B, TM4SF3, and ATPA2) had a
downregulation rate of >29.4% of the total patients after
treatment with CCRT. Additionally, one gene (MET ) had an
upregulation rate of >20% of the total patients after
treatment with CCRT. These differentially expressed genes
show potential to be predictive markers for CCRT efficacy.
Both upregulation of CK-20, ELAVL4, EV12B, TM4SF3, and
ATPA2 genes that can be detected in the tumor of patients
prior to CCRT and upregulation of MET gene that can be
detected in the tumor after treatment with low-dose ra-
diation can indicate the radiosensitivity. Through either
kind of detection methods, it can provide the predictive
results of treatment efficacy for the clinician prior to
applying the CCRT to patients.
However, because of the small sample size analyzed in
this study, there was no statistically significant correlation
between the expression of the 15 genes and the clinico-
pathological features of the CRC patients. In addition, up-
and downregulation rates of the 15 genes in the CRC pa-
tients after treatment with CCRTwere not very high. Higher
patient numbers would help increase the sensitivity in
detecting any differences, if they exist. Therefore, further
investigation should be conducted with a large number of
samples to verify any potential clinical value. It is hoped
that the study results can help clinicians plan an effective
course of treatment.
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